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The nuclear transcription factor Peroxisome proliferator-activated receptor 
gamma (PPARγ) is a negative regulator of macrophage activation and inflammatory 
mediators.  Alveolar macrophages of healthy individuals constitutively express PPARγ. 
Decreased activity and expression of PPARγ are observed in the alveolar macrophages 
from patients suffering from inflammatory conditions such as pulmonary alveolar 
proteinosis (PAP) and sarcoidosis.  These finding suggest that PPARγ activity may have 
an integral role in maintaining lung homeostasis.  This study tested the hypothesis that 
microRNA expression would be dysregulated in murine alveolar macrophages deficient 
in PPARγ.  microRNA (miR) are small non-coding RNA molecules that post-
transcriptionally regulate the expression of messenger RNA.  
Evaluation of microRNA in the murine model of PAP, the GM-CSF-KO mouse, 
demonstrates the elevation of miR-27a and miR-27b which target PPARγ.  The 
deficiency of PPARγ and the lipid transporters ABCA1 and ABCG1 have been shown to 
contribute to the pathology of PAP.  The microRNA miR-33-3p and miR-33-5p, which 
target these lipid transporters, were also elevated in GM-CSF-KO mice.  Pulmonary 
granulomas comparable to those observed in pulmonary sarcoidosis are induced by 
  
instillation of multiwall carbon nanotubes (MWCNT) in C57Bl/6 mice. These animals 
have decreased PPARγ activity and show elevated expression of miR-27a and miR-27b.  
It was also observed that the expression of the transporters ABCA1 and ABCG1 were 
decreased in MWCNT instilled mice.  Expression of miR-33-3p and miR-33-5p was 
elevated in MWCNT instilled animals.  The expression of microRNA that affects the 
activity of NF-κB is also elevated in both murine models. 
We next investigated the use of PPARγ agonist rosiglitazone on the expression 
of microRNA and messenger RNA.  The use of rosiglitazone altered the expression of 
microRNA in both GM-CSF-KO and C57Bl/6+MWCNT mice.  Rosiglitazone treatment 
altered the expression of the lipid transporter ABCA1and ABCG1 in C57Bl/6+MWCNT 
mice.  The elevation of proinflammatory cytokines was also observed.   
Taken together, these observations support the hypothesis that PPARγ activity 
effects the microRNA and gene expression in alveolar macrophages which is critical to 
overall lung homeostasis.  Understanding the relationship between PPARγ and 
microRNA in alveolar macrophage biology will provide insight into the regulation of the 
lung environment and possible therapeutic targets. 
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Chapter1: Introduction 
 
1.1 Alveolar Macrophage: 
For more than 100 years macrophages have been defined by their 
phagocytic abilities.  In his original descriptions of innate immunity, Metchnikoff 
credited phagocytes with influencing development, ensuring homeostasis, and 
protecting the host from infection [1].  Macrophages are distributed throughout 
the body and named according to the tissue in which they reside. Alveolar 
macrophages are derived from circulating monocytes or from the present self-
renewing alveolar macrophage population in the lung [2,3].  The unique lung 
environment with the presence of oxygen and surfactant plays a prominent role 
in shaping the phenotype of the alveolar macrophage.  These features can be 
reproduced when either peritoneal macrophages or bone marrow macrophages 
are transferred into the lung [2]. 
1.2 GM-CSF-Knockout Mouse 
Granulocyte macrophage-colony stimulating factor (GM-CSF) was initially 
thought to only be a hematopoietic growth factor but surprisingly when GM-CSF 
is disrupted in a murine model no hematopoietic abnormalities were detected.  
GM-CSF knockout mice (GM-CSF-KO) have lung pathology similar to that of the 
human disease pulmonary alveolar proteinosis (PAP) [4,5].  In the GM-CSF-KO 
mouse surfactant builds up in the lung and lipid laden alveolar macrophages 
mirror those observed in patients afflicted with PAP [4].  When given exogenous 
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GMCSF therapy, the lung pathology resolves in both PAP patients and the GM-
CSF-KO mice [6,7].        
In an effort to determine a mechanism in which GM-CSF regulates both 
the overall lung environment and the alveolar macrophage, Thomassen et al. 
evaluated the expression of peroxisome proliferator-activated receptor gamma 
(PPARγ).  PPAR-γ which is regulated by  GM-CSF, is known to regulate lipid and 
glucose metabolism as well as inflammatory genes [3].  A potential pathway for 
GM-CSF mediated lung homeostasis through the regulation of PPARγ was 
proposed [8].   
Evaluation of PPARγ in the alveolar macrophages from both PAP patients 
and the GM-CSF-KO model revealed a deficiency of both mRNA and nuclear 
translocation of the protein [6].  Other lipid metabolic genes found to be 
dysregulated in both PAP patients and GM-CSF-KO mice were lipid transporters 
ABCA1 and ABCG1 are upregulated and downregulated, respectively [6].  When 
patients were treated with exogenous GM-CSF, Bonfield et al. reported an 
increase in PPARγ expression to control levels [8].  Correction of ABCG1 
deficiency was observed in primary alveolar macrophages from PAP patients and 
GM-CSF-KO mice cultured with GM-CSF, or from PAP patients receiving GM-
CSF therapy [6].  Thomassen et al. verified the pivotal role of PPARγ in this 
system by utilizing a lenti-viral-PPARγ transduction system in primary human 
alveolar macrophages in vitro; the expression of ABCG1 was significantly up 
regulated compared to lenti-eGFP control cultures [6].  Human alveolar 
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macrophages from PAP patients cultured with the selective PPARγ ligand, 
Rosiglitazone, also exhibited increased gene expression of ABCG1 [6]. These 
data demonstrate the upstream regulation of PPARγ by extracellular GM-CSF as 
well as the importance of PPARγ to alveolar macrophage homeostasis.  
1.3 Peroxisome Proliferator-Activated Receptor-gamma: 
Peroxisome proliferator-activated receptors (PPARs) belong to the 
nuclear-receptor superfamily, reviewed by Smith et al [9].  There are three PPAR 
isoforms: PPAR-α, PPAR-β/δ, and PPAR-γ.  The PPARs are transcribed from 
unique genes but share a common protein structure [10].  Each of the 
transcription factors work in a unique fashion with varying tissue distribution, 
reviewed by Tontonoz et al [9,11].  PPARα was first identified to induce 
proliferation of peroxisomes in the liver [9].  PPAR β/δ is prevalent in most 
tissues of the body and is involved in lipid oxidation and keratinocyte 
differentiation [9] [10]. PPARγ is typically associated with adipocytes, for its role 
in lipid and glucose metabolism, but also acts as a negative regulator of pro-
inflammatory mediators  [9] [10]. 
 PPARs regulate gene expression by several different mechanisms, 
including the inhibition of inflammatory mediators, prevention of transcription, and 
regulation of PPARγ response elements [12,13].   PPAR’s can modulate the 
inflammatory response by sequestrating the coactivators of major inflammatory 
regulators including NF-κB, AP-1, and STAT-1, this mechanism is termed 
transrepression [14-16].  In combination with other proteins, PPARγ forms 
complexes which prevent transcriptional activation of inflammatory response 
genes in macrophages (Figure 1:b
specific agonists which include rosiglitazone.  PPAR
promote the localization to PPAR
the expression of target genes (
transcription of particular genes while promoting the expression of others.
Figure 1: Transcriptional activities of the peroxisome proliferator
receptors. PPARs can both activate and inhibit gene expression. (a) Ligand
dependent transactivation. PPARs activate transcription in a ligand
manner by binding directly to specific PPAR
genes as heterodimers with RXR. B
recruitment of coactivator complexes that modify chromatin structure and 
facilitate assembly of the general transcriptional machinery to the promoter. (b) 
Ligand-dependent transrepression. PPARs repress transcription 
dependent manner by antagonizing the actions of other transcription factors
(yellow), such as nuclear factor
ligand-independent repression. PPARs bind to response elements in the 
absence of ligand and recruit corepressor complexes that mediate active 
repression. This complex antagonizes the actions of coactivators and maintains 
genes in a repressed state in the absence of ligand.
2007 [13]). 
 
) [12].  These effects are promoted by PPAR
γ ligands, when bound
γ-response elements which promote or prevent 
Figure1: a) [13].  A single ligand can inhibit the 
-activated 
-dependent 
-response elements (PPRE) in target 
inding of agonists ligand leads to the 
in a ligand
-κB (NF-κB) and activator protein-1 (AP
  (Adapted from Ricote et al 
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-
-
 
-1). (c) 
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To investigate the specific role of PPARγ in lung homeostasis, Malur et al 
utilized a conditional PPARγ-knockout murine model (PPARγ−KO) The strain is 
deficient of PPARγ in myeloid cells which include macrophages and neutrophils.  
In the PPARγ-KO model GM-CSF is active and its expression is unchanged from 
that of C57/Bl6 mice [17]. The PPARγ-KO mice exhibit lipid loaded “foamy” 
alveolar macrophages that are similar but have less lipid accumulation than the 
GM-CSF-KO alveolar macrophage.   Evaluation of the lipid transporters ABCA1 
and ABCG1 showed dysregulation matching that of pulmonary alveolar 
proteinosis patients and GM-CSF-KO mice: i.e. the upregulation of ABCA1 and 
downregulation of ABCG1 [18].  The use of a lenti-viral expression vector (lenti-
PPARγ) to restore PPARγ in the alveolar macrophages reversed the down 
regulation of ABCG1 as well as other cholesterol efflux genes [18,19].  
 The pulmonary response in the PPARγ knockout model was 
characterized as a TH-1 associated inflammatory response by Malur et al [20].  It 
was observed that in the absence of PPARγ, Interferon-γ (IFN-γ) levels were 
elevated and led to an increase in inducible nitric oxide synthase (iNOS) in the 
alveolar macrophages of PPARγ-KO mice.  Total leukocytes were increased in 
the PPARγ-KO mice and the percentage of lymphocytes was elevated compared 
to C57/Bl6 controls with a predominance of CD8+ versus CD4+ T cells.   
Evaluation of TH-1 associated cytokines in addition to IFN-γ revealed increased 
production of IP-10 (CXCL10), MIP-1α, and IL-12 (p40) in BAL cells and BAL 
fluid collected from the PPARγ-KO mice [20].   
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 To confirm that the absence of PPARγ promoted an inflammatory 
phenotype in alveolar macrophages, BAL cells from C57/Bl6 wild type animals 
were cultured with PPARγ specific antagonist GW9662.  Ex vivo macrophages 
cultured with GW9662 showed increased IFNγ and iNOS expression and, as 
expected, decreased PPARγ expression. IFNγ or iNOS could not be detected in 
control cultures.  Immunocytochemistry confirmed these data showing an inverse 
relationship between PPARγ and IFNγ and iNOS in GW9662 positive or control 
cultures [20].  Interestingly when the alveolar macrophages from PPARγ-KO mice 
were cultured with neutralizing anti-IFNγ for 24 hours, iNOS expression was 
significantly decreased.  Malur et al. postulated that PPARγ antagonizes the 
expression of IFNγ thereby preventing the activation of iNOS, thus controlling 
nitric oxide expression in the lung [20].  
1.4 Sarcoidosis and PPARγ Deficiency 
Sarcoidosis is a multisystem disease characterized by the presence non-
necrotizing granulomas and more than 90 percent of afflicted individuals have 
pulmonary involvement [21].  Diagnosis of sarcoidosis is made by eliminating 
other possible causes.  Clinical radiographic findings can suggest sarcoidosis but 
require biopsy-proven histopathology and the exclusion of infectious 
granulomatous diseases for a valid diagnosis of sarcoidosis  [22]. 
Contributing to the hypothesis that PPARγ contributes to overall lung 
homeostasis is the observation that PPARγ expression is decreased in 
pulmonary sarcoidosis, and the disease can be characterized as an ongoing TH1 
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inflammatory phenotype [21, 22].  Culver et al collected BAL samples from eight 
patients with active sarcoidosis and nine healthy volunteers.  It was observed 
that PPARγ gene expression, binding activity, and nuclear localization were 
decreased in patients with active sarcoidosis compared to normal controls.  The 
group also noted an increase in NF-κB binding activity in the same patients 
evaluated for the PPARγ [21].  In addition to NF-κB, the expression of IFNγ was 
increased.  [21,22]. 
Studying the etiology and progression of sarcoidosis has been a 
challenging research question.  Difficulties have been noted when eliciting 
granuloma formation in animal models. Most of these models involve intravenous 
injection of antigen-bound sepharose beads [23,24].    The major drawback of 
these models is the rapid resolution of the granuloma structure (14-21 days).  
This feature makes it difficult to distinguish the effects of the initial injury from the 
resolution of the granuloma [25].  The observation that nanomaterials produced 
granuloma like lesions in the lung of animal models prompted Huizar et al. to 
investigate the use of multi wall carbon nanotubes (MWCNT) to produce a 
chronic model of pulmonary granulomatous disease [26-28] 
1.5 Carbon Nanotubes  
Nanomaterials represent a broad range of particles that are characterized 
by their extremely small size, with at least one physical dimension less than 
100nm.  Carbon nanomaterials can be the byproduct of combustion and can be 
produced from wood or gas burning stoves or products of engine exhaust [26].  
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Postmortem examination of the lungs of firefighters has shown the presence of 
granulomas [29,30].  Carbon nanotubes can be found as two types, single walled 
or multi walled.  As the name implies, multiwall carbon nanotube have several 
concentric layers of carbon compared to the single walled carbon nanotubes.  
Intratracheal instillation of MWCNT in C57/Bl6 mice yielded well-formed 
granulomas persistent up to 90 days post instillation.  It was also observed 
through the use of immunocytochemistry that macrophages and CD3+ T-cells 
localized to the site of the granuloma. The elevation of inflammatory cytokines 
was also found in MWCNT instilled animals including CCL2 and IL-10 [25].  A 
consecutive paper published by Huizar et al demonstrated the reduction in 
mRNA, nuclear localization, and binding activity of PPARγ in wild-type mice 
instilled with MWCNT [31].  Instillation of MWCNT in PPARγ KO mice 
exacerbates granuloma formation and elevation of inflammatory cytokines 
further, compared to C57Bl/6 mice instilled with MWCNT [31].    In another study, 
alveolar macrophages from MWCNT instilled C57Bl/6 mice were evaluated for 
gene expression characteristic of an M1 or M2 macrophage activation 
phenotype.  Elevation of M1 associated genes was observed while M2 
associated genes were not significantly different or were downregulated with the 
exception of CCL2 and IL-10 which had been previously reported [25,32].  The 
observations in the MWCNT model corresponds with the PPARγ deficiency and 
granulomatous histopathology observed in sarcoidosis.   
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1.6 microRNAs – Potential Regulators in Pulmonary Disease 
The role of microRNA in chronic granulomatous disease or alveolar 
macrophage PPARγ deficiency has not been clarified.  microRNA are small 
noncoding RNA that provide post transcriptional gene regulation by blocking 
translation or destabilizing their target messenger RNA (mRNA). microRNA are 
traditionally transcribed by RNA polymerase II from non-coding regions or are 
introns of protein coding genes [33].  Transcribed microRNA molecules fold back 
onto themselves forming a distinct hairpin loop termed a pri-miRNA.  pri-miRNA’s 
are cleaved by the enzyme Drosha into a shorter ~70 nucleotide hairpin and 
exported into the cytoplasm, the microRNA are now termed pre-miRNA.  Further 
cleavage by the enzyme Dicer yields a shorter miRNA/miRNA duplex which 
consist of two microRNA [33].  The two microRNA are distinguished by their 
original orientation on the DNA.  One side of the microRNA duplex will be 
incorporated into the miRNA-induced silencing complex (mRISC).  The mRISC is 
a large protein complex which incorporates a mature microRNA sequence which 
provides a guide to target the appropriate mRNA for silencing or degradation.  
Position of Drosha and Dicer cleavage determines the mature sequence of the 
mature microRNA and could determine the side of the duplex to be incorporated 
to mRISC [33]. 
 microRNA nomenclature consist of an identification number which are 
assigned in order of discovery, miR-23 was predicted or confirmed before miR-
199. Some microRNA are transcribed from two locations in the genome and 
share a common mature sequence, these are identified by a letter following the 
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identification number, such as miR-27a and miR-27b.  Based on the original 
orientation to the RNA, each mature microRNA has two sides to its stem loop 
designated by a 3p or 5p and are distinct microRNA.  miR-27a-3p and miR-27a-
5p are located beside one another in the genome but have unique seed regions 
and sequences, some of which overlap as a stem loop.  During processing 
microRNA can be analyzed at varying states of maturity and have unique 
prefixes that were highlighted above and are written with a lower case ‘r’.  In 
order of maturity miR-27a-3p would be listed:  pri-mir-27a-3p, pre-mir-27a-3p, 
and finally the mature miR-27a-3p 
 Incorporation into an mRISC allows microRNA to become functional 
however the mechanism of targeting mRNA has only began to be delineated in 
the past several years.  The mRNA targeted for degradation is determined by 
several factors, the first of which is the seed region.  The microRNA seed region 
refers to base pairs 2-7 on the mature microRNA strand. Identification of 
complimentary sequence in the mRNA 3’ untranslated region and using those 
with orthologs from other species greatly increases target prediction [34].  Other 
factors concerning the remaining ~15 nucleotides may contribute to stability, 
mRNA selection or mRISC incorporation but there is not a consensus on the 
functions of the entire microRNA [34].   
 microRNA have been shown to be important effectors of the inflammatory 
process [35-37].  The direct regulation of microRNA by inflammatory mediators 
including NF-κB is involved in inhibitory loops providing possible feedback 
mechanisms [37].  Crouser et al conducted microarray analysis of lung tissue 
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and peripheral mononuclear cells from patients suffering from pulmonary 
sarcoidosis and observed an increase in microRNAs targeting the TGFβ pathway 
[35].  TGFβ is produced by alveolar macrophages and is thought to suppress T-
cell activation [3].  Examination of microRNAs potentially affecting PPARγ, 
however, was not done, and bronchoalveolar lavage cell preparations were not 
studied. 
 
1.7 Hypothesis 
 The hypothesis underlying this thesis is that alterations in microRNA 
expression are involved with alterations in alveolar macrophage PPARγ 
expression.    To study this hypothesis, experiments will be designed to examine 
microRNA in mice with:  a macrophage-specific PPARγ knockout, PPARγ 
deficiency due to GM-CSF knockout, and PPARγ deficiency due to the presence 
of inflammatory granulomatous disease (the MWCNT granuloma model).  The 
results and discussion of this thesis will be presented in two parts. In chapter 3, 
studies characterizing the PPARγ-KO and GM-CSF-KO will be presented and 
discussed.  In chapter 4 the studies with the model of chronic granulomatous 
disease will be presented and discussed. 
  
Chapter 2:  Materials and Methods 
 2.1 Mice: All studies were conducted with approval from East Carolina 
University Institutional Animal Care Committee (AUP#J185c and #J199a) 
Evaluation of basal microRNA expression from the three strains: C57Bl/6, 
PPARγ-KO, and GM-CSF-KO mice were conducted with animals 8-12 weeks of 
age with gender matched controls.  C57Bl/6 wild type mice were purchased from 
Jackson Laboratories and set up as breeding pairs at 7 weeks of age. C57Bl/6 
breeders were replaced approximately every six months.  The pups of these 
C57Bl/6 breeding pairs were used for consecutive experiments as control 
animals.  Macrophage specific PPARγ-KO mice are deficient of PPARγ in cells of 
the myeloid lineage and have been described previously [20].  Homozygous 
floxed PPARγ mice (flox +/+) were obtained from Dr. F.J. Gonzalez at the 
National Institute of Health, Bethesda, MD.  These mice were crossed with 
transgenic animals obtained from Jackson Laboratories with the CRE gene under 
the control of the murine lysozyme M gene (cre+/+).  Mice were genotyped and 
mated to produce flox+/+/cre+/+ animals.  Those mice possessing either flox-/-/cre+/+ 
or flox+/+/cre-/- did not show any difference from C57Bl/6 controls in initial 
experiments by Malur et al [20].  Mice from the flox+/+/cre+/+ lineage are used in 
these experiments as PPARγ-KO mice. GM-CSF-KO mice were previously 
attained from the lab of Dr. G Dranoff.  The GMCSF-KO mouse was produced by 
homologous recombination in embryonic stem cells [4].    Both PPARγ-KO and 
GM-CSF-KO mice are on C57Bl/6 backgrounds and are compared to C57BL/6 
controls as described from Jackson Labs. 
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 2.2 Instillation of Multi Wall Carbon Nanotubes:  Multi Wall Carbon 
Nanotubes (MWCNT) were suspended in 35% INFASURF(calfactant), in 
phosphate buffered saline (PBS) at a concentration of 100µg/ 50µL.  35% 
surfactant and MWCNT were sonicated in a water bath for 5 minutes and 
checked visually for any remaining large particles.  Mice were sedated with 
isofluorane in a chamber until unresponsive.  Oropharyngeal instillation of 
MWCNT were performed by pulling the tongue forward with forceps and instilling 
50µL-volume of MWCNT suspension into the airway.  The tongue was held out 
while the MWCNT were aspirated into the lung and released as the animal began 
to show signs of sensation.  Retaining the tongue outside the oral cavity ensures 
the MWCNT’s are aspirated and not swallowed. All procedures were conducted 
in accordance with East Carolina University Office of Environmental Health and 
Safety within a HEPA filtered laminar flow hood.   
 
2.3 Bronchoalveolar Lavage (BAL):  BAL cells were collected from 
animals euthanized with Ketamine (90mg/kg) and Xylazine (10mg/kg) injected 
intraperitoneal.  Animals were placed in a supine position and the trachea was 
exposed and cannulated with plastic tubing (PlasticsOne) on a 20G needle.  
Whole lung lavage was conducted with warmed 20% lidocaine in PBS at 1mL 
aliquots X 5 for a total or 5mL and collected on ice.  Collections were spun at 
1800 RPM for 10 minutes at 4οC to yield a cell pellet.  Cell pellets were 
resuspended in 2mL cold PBS and cell count was performed with 10µL cell 
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suspension on hemocytometer and differential cell count were obtained from 
cytospins with 150µL cell suspension stained with modified Wright’s stain.  BAL 
cell differentials for all animals used in the following experiments had >90% 
macrophages.  Cytospin preparations were also evaluated for any significant 
epithelial cell contamination that may have sloughed off during BAL collection or 
resulted from the insertion of the tubing into the trachea. Cell pellets were 
washed again in cold PBS, supernatant was removed and pellet was stored at -
80οC.   
 
 2.4 RNA Purification and Quantification:  Total RNA was collected from 
BAL cell pellets using the miRNeasy Micro Kit (Qiagen) according to 
manufactures protocol.  Total RNA (mRNA and microRNA) was eluted in 30µL 
water.  Quantification was conducted with Nanodrop 1000 (Thermo scientific).  
 Reverse transcription of messenger RNA (mRNA) was performed with the 
RT2 First Strand kit (Qiagen) to produce cDNA for protein coding genes. mRNA 
quantification was conducted with Real-Time Polymerase Chain Reaction (RT-
PCR) using with RT2 SYBR Green/ROX qPCR Master Mix (Qiagen).  Relative 
quantification of mRNA cycle threshold values (CT) were compared to those of 
the house keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).  
The expression changes were calculated using the 2-ΔΔCt method [38]. 
 microRNA were reverse transcribed utilizing the miScript II RT Kit 
(Qiagen). The miScript kit has two separate buffers hiFlex, which amplifies all 
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RNA’s and hiSpec, which selectively amplifies small RNA’s.  Utilizing the hiSpec 
buffer, long RNA strands such as mRNA are repressed, and small noncoding 
RNA’s such as miRNA and small nuclear RNA( snorRNA) are polyadenylated. 
After addition of the poly-A tail, small RNA’s are reversed transcribed.  Both 
messenger RNA (mRNA) and microRNA were quantified using RT-PCR.  
microRNA were quantified with miScript SYBR Green PCR Kit (Qiagen).  
Relative quantification of microRNA CT values was compared to those of 
SNOR68, a small nuclear RNA. dCT values were calculated as described above 
and used for further analysis.  
 The amount of total RNA was used to standardize the amount of 
microRNA that is needed for down-stream applications.   For both mRNA and 
microRNA, 300-500ng of total RNA was converted with the appropriate cDNA kit 
and assumed that a 1:1 RNA:cDNA conversion took place. For downstream 
analysis, 2ng of cDNA was used to standardize the RT-PCR reactions further.  
 
 2.5 Cell Culture Assays:  BAL collections were pooled from animals of 
the same strain to get enough cells for in vitro culture. BAL cells were collected 
as described with the exception that cells were kept at room temperature during 
collection, to prevent loss of cell adhesion.  Medium was warmed in a 37οC water 
bath and used to wash BAL cells two times and cell count was determined by 
hemocytometer.  Medium consisted of RPMI medium supplemented with 10% 
fetal bovine serum and 1% PSG (pen-strep-glutamine). BAL cells were plated at 
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1.2x106 cells/well in a 12 well plate.   Cells were incubated at 37οC (5% CO2) for 
two hours then washed twice by adding 1mL media further.  Cells were then 
allowed to adhere for twenty-four hours prior to adding stimulus. 
Stimuli were diluted as follows:  Lipopolysaccharides from salmonella 
enterica serotype typhimurium (LPS) (Sigma Aldrich).  LPS was suspended and 
diluted to a concentration of 1.0 mg/mL in sterile PBS.  Prior to use, LPS was 
diluted to 0.1µg/mL in cell culture medium and 1mL was added in appropriate 
well. Rosiglitazone (Rosi) and GW9662 (GW) (Cayman Chemicals) were 
resuspended in 1:1 DMSO:PBS mixture to a concentration of 10mM and stored 
at -20οC. Prior to use Rosi and GW were diluted according to manufacturer’s 
instructions to 10µM concentration for stimulation.  Cell cultures were stimulated 
with medium alone, LPS, Rosi, GW, LPS+Rosi, or GW+Rosi. Stimulus were 
added for either 6 or 24 hours at which time total RNA was collection as 
previously described.  RNA was reverse transcribed with the respective kits for 
mRNA and microRNA and RT-PCR with the appropriate reagents as described 
above.   
 2.6 Rosiglitazone I.P. Treatment:  The rosiglitazone as described above 
was dissolved in DMSO:PBS at a 1:1 ratio at a concentration of 25mg/mL.  
Aliquots of 180uL was stored at -20οC and resuspended in PBS to 1.7 mL to 
bring the concentration to 0.08µg/µL.  Mice age 8-10 weeks were weighed on 
day one and given 3.0mg/kg body weight ROSI via intraperitoneal (IP) injections.  
Injections were performed in four locations, two on each side of the animal 
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rotating in a clockwise manner.  Rosi was administered 10 consecutive days prior 
to BAL collection. 
 
2.7 Statistical Analysis:  Individual BAL samples collected or those data 
from cell culture experiments were analyzed by student’s t-test using Prizm 
software (GraphPad, Inc., San Diego, CA.)  Values from control animals were 
compared to treated group and a difference of p≤0.05 was considered significant.  
Data are shown as mean ± SEM.   
 
  
Chapter 3: Evaluation of microRNA Expression in GM-CSF and PPARγ 
Knockout Mice 
Results: 
3.1 miRNA-27b-3p is upregulated in alveolar macrophages from PPARγ-KO 
and GM-CSF-KO mice 
microRNA miR-27a-3p and miR-27b-3p have been shown to 
downregulate PPARγ mRNA and may be promoted by inflammation [39].  
Alveolar macrophages from C57/Bl6, PPARγ-KO, and GM-CSF-KO mice were 
evaluated (Figure 2).   miR-27a-3p expression was not significantly different in 
the PPARγ-KO mice but was significantly increased 1.4  fold in the GM-CSF-KO, 
compared to C57/Bl6 controls.  However, miR-27b-3p was significantly elevated 
in both models, increasing 2.9 fold in the PPARγ-KO mice and 4.2 fold in the GM-
CSF-KO mice.  These  results suggest that miR-27b-3p may be involved in the 
regulation of PPARγ. 
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Figure 2: Expression of microRNAs targeting PPARγ are up regulated in the alveolar 
macrophages from PPARγ-KO and GMCSF-KO mice. Graphs represent mean fold change ±SEM 
compared to C57/Bl6 control animals. 
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Figure 3: Expression of microRNA associated with NF-κB activity was evaluated in alveolar 
macrophages from C57Bl/6, PPARγ-KO and GM-CSF-KO mice. Graphs represent mean fold 
change compared to C57/Bl6 control animals. 
3.2 miRNAs associated with NF-κB regulation are upregulated in alveolar 
macrophages from PPARγ-KO and GM-CSF-KO mice 
Both PPARγ-KO and GM-CSF-KO models show elevated NF-κB activity in 
the alveolar macrophage compared to C57Bl/6 control animals (unpublished 
data). The expression of microRNAs which antagonize the activity of NF-κB 
(miR-23b-3p, miR-146a-5p, and miR-199a-3p) [39,40] were evaluated (Figure 3). 
The upregulation of these microRNA may provide a negative feedback loop for 
NF-κB [39,40].  The expression of miR-23b-3p was elevated 6.9 fold in PPARγ- 
KO alveolar macrophages, and 12 fold in the BAL cells of GM-CSF-KO mice.  
The expression of miR-146a increased 7.4 fold in the PPARγ-KO and 45.3 fold in 
the GM-CSF-KO BAL cells.  The expression of miR-199a was elevated 3.7 fold in 
PPARγ-KO BAL cells and 27.9 fold in GM-CSF-KO BAL cells. Thus all of the 
microRNA evaluated which are associated with NF-κB regulation were 
upregulated in mice with deficient PPARγ. 
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3.3 miRNA targeting ABC Transporters in alveolar macrophages from 
PPARγ-KO and GM-CSF-KO mice are upregulated 
Previous studies have shown the dysregulation of ABCA1 and ABCG1 
lipid transporters contributes to lipid loading of alveolar macrophages from 
PPARγ-KO and GM-CSF-KO mice [6,19].  PPARγ has been shown to regulate 
ABCG1 expression [18]. Recently miR-33 has been associated with the 
regulation of ABCA1 and ABCG1 [41,42], but the status of these microRNAs in 
alveolar macrophages is unknown.  Because of the possible involvement in lipid 
metabolism, miR-33-3p and miR-33-5p were evaluated (Figure 4).  The alveolar 
macrophages from PPARγ-KO mice show upregulation of miR-33-3p (26 fold) 
and miR-33-5p (8.7 fold).  GM-CSF-KO alveolar macrophages show an increase 
in miR-33-3p (2.5 fold).  miR-33-3p and miR-33-5p were strongly upregulated in 
the alveolar macrophages from PPARγ-KO but surprisingly only miR-33-3p was 
upregulated in the GM-CSF-KO mice. 
 
 
 
 
 
 
Figure 4: miR-33-3p and miR-33-5p expression in GM-CSF-KO and PPARγ-KO was 
evaluated by RT-PCR in alveolar macrophages.  Graphs represent mean fold change 
compared to C57/Bl6 control animals. 
miR-33-3p
C57/Bl6 PPARγ-KO GMCSF-KO
0.0
2.5
5.0
20
25
30
p < 0.04 as compared to C57/Bl6


n=4               n=7              n=4
m
iR
NA
 
Fo
ld
 
Di
ffe
re
n
ce
 
miR-33-5p
C57/Bl6 PPARγ-KO GMCSF-KO
0
2
4
6
8
10
p < 0.001 as compared to C57/Bl6

n=5               n=8              n=8
m
iR
NA
 
Fo
ld
 
Di
ffe
re
n
ce
 
21 
 
GMCSF-KO+DMSO GMCSF-KO+Rosi
0.0
0.5
1.0
1.5
miR-27b-3p
n=7                        n=7

Re
la
tiv
e 
Fo
ld
 
Ch
an
ge
=p=0.04
  
Figure 5: Expression of miR-27b-3p in rosiglitazone treated GM-CSF-KO is suppressed in 
alveolar macrophages. Graphs represent mean fold change compared to vehicle control 
animals. 
3.4 In vivo rosiglitazone treatment effects microRNA expression in GM-
CSF-KO mice.  
 We hypothesized that residual PPARγ may be present in the alveolar 
macrophages of the GM-CSF-KO mice and treatment with rosiglitazone (a 
synthetic ligand for PPARγ) may alter microRNA, gene expression, and enhance 
lipid clearance from alveolar macrophages.  We evaluated the expression of 
miR-27a-3p and miR-27b-3p after rosiglitazone treatment (Figure 5).  miR-27b-
3p expression was 60% less than that of the vehicle control group.  The alveolar 
macrophages from these animals were collected and stained with modified 
Wrights stain.  No difference in the foamy morphology of the alveolar 
macrophages was observed (n=7/treatment) suggesting no decrease in lipid 
loading.   Neither PPARγ mRNA expression nor miR-27a-3p was altered in the 
rosiglitazone treated mice compared to vehicle controls. 
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3.5 In vivo rosiglitazone treatment does not affect lipid transporters or 
microRNA associated with NF-κB activity in GM-CSF-KO mice  
 The expression of lipid transporters ABCA1 and ABCG1 have been shown 
to be dysregulated in the GM-CSF-KO mouse and play a role in regulating 
cholesterol efflux [18].  No significant difference was observed between 
rosiglitazone treated mice and controls in either ABCA1 or ABCG1 expression in 
alveolar macrophages.  The expression of miR-33-3p and miR-33-5p, which 
target ABCA1 and ABCG1 is not affected by rosiglitazone treatment.  No 
differences were observed in miR-23b-3p, miR-146a-5p, or miR-199a-3p, which 
effect NF-κB expression.   
 
3.6 In vivo rosiglitazone treatment effects microRNA expression in PPARγ-
KO mice. 
  As a negative control for the rosiglitazone experiments conducted with 
GM-CSF-KO mice the PPARγ-KO mice were treated with rosiglitazone due to the 
lack of functional PPARγ. The expression of miR-33-5p was up regulated 24 fold 
(p<0.001) (Figure 6).  The expression of miR-27a-3p, miR-27b-3p, miR-33-3p, 
miR-146a-5p, and 199a-3p is not statistically different. ABCA1 and ABCG1 were 
also evaluated in the PPARγ-KO mice treated with rosiglitazone and no 
difference was observed compared to the control group.  
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Figure 6:  PPARγ-KO mice treated with rosiglitazone demonstrate a 24 fold increase in 
miR-33-5p expression.  Graphs represent mean fold change compared to vehicle control 
animals. 
 
The data collected from the PPARγ and GM-CSF knockout animals 
suggested that a deficiency of PPARγ expression in the alveolar macrophage 
effects the microRNA expression of these cells.  The use of the PPARγ specific 
agonist rosiglitazone effects microRNA and gene expression in the alveolar 
macrophages from these knockout models.  To further investigate the 
mechanism in which PPARγ effects microRNA expression in alveolar 
macrophages, we performed in vitro stimulation with LPS.  Stimulation with LPS 
is known to downregulate the expression and activity of PPARγ.  The 
costimulation with known PPARγ agonist rosiglitazone and antagonist GW9662 
may provide insight into the specific regulation of microRNA in activated 
macrophages.  We hypothesized that microRNA expression would mirror that 
observed in the PPARγ-KO and GM-CSF-KO mice.   
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Figure 7:  Expression of microRNA 146a-5p in C57Bl/6 alveolar macrophages cultured with 
LPS, ROSI (PPARγ agonist), or GW9662 (PPARγ antagonist) for 6 or 24 hours. Graph 
represents fold change compared to unstimulated controls or to LPS alone.  
3.7  Regulation of miR-146-5p in alveolar macrophages in vitro  
The observation that elevated miR-146a-5p was associated with PPARγ 
deficiency in the PPARγ and GMCSF knockout mice led to the hypothesis that 
downregulation of PPARγ activity in wild-type C57/Bl6 alveolar macrophages 
would alter microRNA expression.   
 At 6 and 24 hour time points, neither ROSI nor GW9662 alone showed 
any change in miR-146a-5p compared to unstimulated (US) controls as 
anticipated. In contrast, at both 6 and 24 hours, LPS significantly stimulated miR-
146-5p. Addition of ROSI to LPS reduced miR-146a-5p levels at 24 hours.  
Cultures with GW9662 and LPS had no effect on miR-146a-5p levels. These 
results suggest that PPARγ deficiency (as has been shown with LPS stimulation) 
elevated miR-146a-5p while PPARγ activation reduces expression (Figure 7).  No 
difference was observed in the expression of miR-27a-3p, miR-27b-3p, miR-33-
3p, miR-33-5p, or miR-199a-3p. 
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Summary and Discussion: Chapter 2 
 This study is the first to evaluate the microRNA expression in alveolar 
macrophages with PPARγ deficiency.  microRNAs associated with inflammation, 
the regulation of PPARγ, and control of lipid transporters were evaluated. 
Alveolar macrophages from the GM-CSF-KO and PPARγ-KO mice have a pro-
inflammatory phenotype which is reflected in elevated NF-κB activation.  The 
GM-CSF-KO mice are sensitive to inflammatory stimuli and have higher NF-κB 
activation when compared to the PPARγ-KO mice (unpublished observation).  
The expression of miR-23b-3p, miR-146a-5p, and miR-199a-3p reflect this 
phenotype. Each of these microRNA are elevated in the PPARγ-KO and further 
elevated in the GM-CSF-KO alveolar macrophages (See summary, Table 1).   
 The microRNA miR-27a-3p and miR-27b-3p have been shown to 
destabilize PPARγ mRNA [39].  miR-27a-3p expression was significantly 
elevated only in the GMCSF-KO mice while miR-27b-3p expression had 
definitive increases in both strains.  The fact that only miR-27b is upregulated in 
the PPARγ-KO suggests that the deficiency in GM-CSF (PPARγ-KO mice are not 
deficient in GM-CSF) may be affecting miR-27a. These data suggest that miR-
27a and miR-27b upregulation may contribute to the deficiency of PPARγ in GM-
CSF-KO alveolar macrophages.   
 The lipid transporters ABCA1 and ABCG1 have been shown to contribute 
to surfactant catabolism and regulation of lung homeostasis. These transporters 
are dysregulated in both the PPARγ-KO and GM-CSF-KO alveolar macrophages.  
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The microRNA miR-33-3p and miR-33-5p target ABCA1 and ABCG1 in other cell 
types.   The microRNA-33-3p was elevated in the PPARγ-KO and GM-CSF-KO 
mice while miR-33-5p was elevated only in the GM-CSF-KO. The high increase 
in both of these microRNA in the PPARγ-KO and not the GM-CSF-KO mice may 
suggest that the miR-33-5p is related to the GM-CSF deficiency and not related 
to ABCG1 deficiency which occurs in both strains.  
 microRNA expression was evaluated in vitro cultures of alveolar 
macrophages from C57Bl/6 mice stimulated with LPS and PPARγ agonist and 
inhibitors. Only miR-146a-5p was stimulated with LPS and decreased with 
rosiglitazone.  PPARγ expression is decreased and NF-κB activity is increased 
upon stimulation with LPS.  The expression of miR-146a is promoted by NF-κB.  
Our stimulation data supports the idea that PPARγ can inhibit NF-κB activation 
and reduce the expression of miR-146a-5p.  The fact that none of the other 
microRNA were stimulated may reflect one or more of the following: (a) in vitro 
versus in vivo settings; (b) LPS stimulation versus deletion of GM-CSF which 
directly reduces PPARγ; (c) or a direct deletion of PPARγ in vivo; or other factors 
in the lung environment participate in the regulation of these microRNA.  Further 
studies may be carried out using GM-CSF stimulation in vitro to attempt further 
understanding of the GM-CSF - PPARγ - ABCG1 pathway and the involvement of 
microRNA. (See Appendix C, Figures A-C) 
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Table 1: Summary of results presented in Chapter 3 
mRNA/microRNA GM-CSF-KO* GM-CSF-KO 
+Rosi** 
PPARγ-KO* PPARγ-KO 
+Rosi** 
PPARγ mRNA Decreased Unchanged Decreased N/A 
ABCA1 mRNA Increased Unchanged Increased Unchanged 
ABCG1 mRNA Decreased Unchanged Decreased Unchanged 
miR-27b Increased Decreased Increased Unchanged 
miR-146a Increased Unchanged Increased Unchanged 
miR-23b Increased Unchanged Increased Unchanged 
miR-199a Increased Unchanged Increased Unchanged 
mIR-33-5p Unchanged Unchanged Increased Increased 
 
* Compared to C57Bl/6  
** Compared to vehicle control 
 
 
(See Appendix C, Figures A-C) 
 
  
Chapter 4: microRNA Expression in Model of Chronic Granulomatous Lung 
Disease 
As mentioned in the introduction, our laboratory interest lies in the 
understanding of human lung disease.  One such goal is to improve the 
understanding of sarcoidosis pathophysiology.  The relatively recent reports of 
carbon nanotubes in the environment favoring sarcoidosis incidence have 
prompted us to develop a model of MWCNT mediated lung disease that might 
have applicability to sarcoidosis [43].  This model has proven to be extremely 
interesting with pathological changes identical to those found in sarcoidosis 
[25,31,32].  Because of the importance of alveolar macrophages and PPARγ 
deficiency in sarcoidosis and this MWCNT model, microRNAs were investigated.   
Results: 
4.1  miRNA-27b-3p is upregulated in alveolar macrophages from C57Bl/6 
mice instilled with MWCNT  
The expression of PPARγ has been shown to be down regulated in 
C57BL/6 mice instilled with MWCNT [31].  The expression of PPARγ was 
monitored in MWCNT instilled mice that were collected for this study; these mice 
show a significant decrease in PPARγ expression, supporting previously 
published data.  The expression of miR-27a-3p and miR-27b-3p were evaluated 
in the alveolar macrophage of C57Bl/6 mice instilled with MWCNT (Figure 8).  
The expression of miR-27b-3p increased 1.7 fold in the MWCNT mice compared 
to vehicle controls. No change was observed in the expression of miR-27a-3p. 
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Figure 8: Expression of microRNA in C57Bl/6 mice instilled with MWCNT.  MWCNT instilled 
mice show increased expression of miR-27b-3p. Graphs represent mean fold change compared 
to vehicle control. 
 
 
 
4.2 miRNA associated with NF-κB regulation are upregulated in C57Bl/6 
mice instilled with MWCNT 
 Activity of NF-κB and inflammatory mediators are increased in alveolar 
macrophages from patients with sarcoidosis [21].  Recently Huizar et al 
published that inflammatory mediators were also elevated in the MWCNT model 
[25].  microRNAs miR-23b-3p, miR-146a-5p, and miR-199a-3p were evaluated in 
the C57Bl/6 mice instilled with MWCNT (Figure 9).  The expression of miR-23b-
3p increased 1.5 fold in MWCNT instilled mice.  miR-146a-5p expression 
increased 2.8 fold in animals instilled with MWCNT.  miR-199a-3p was not 
altered in MWCNT instilled mice.  These data demonstrate upregulation of two 
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microRNA that were elevated in GM-CSF and PPARγ knockout mice, however 
miR-199a-3p was not changed. 
 
 
 
 
 
 
 
 
 
 
 
4.3 ABC Transporters are dysregulated in MWCNT instilled C57Bl/6 mice 
Previous studies have shown the dysregulation of ABCA1 and ABCG1 in 
PPARγ deficient pathologies. ABCA1 and ABCG1 deficiencies have been linked 
to increased inflammatory response to antigens [43]. The expressions of ABCA1 
and ABCG1 are evaluated in MWCNT instilled mice (Figure 10).  ABCA1 
expression in MWCNT instilled mice decreased 40% compared to vehicle control 
animals.  ABCG1 expression decreased 30% in MWCNT instilled animals 
compared to vehicle controls.  The downregulation of both ABC Transporters 
suggest they may play a role in promoting granuloma formation.  
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Figure 9:  Expression of inflammatory microRNA in C57Bl/6 mice instilled with 
MWCNT for 60 days. The expression of miR-23b-3p and miR-146a-5p are elevated in 
alveolar macrophages from C57Bl/6 mice instilled with MWCNT.  Graphs represent 
mean fold change compared to vehicle control. 
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4.4 miRNA targeting ABC Transporters are elevated in C57Bl/6 mice 
instilled with MWCNT 
 The microRNA miR-33-3p and miR-33-5p have been reported to target the 
mRNA of ABCA1 and ABCG1. The expressions of microRNA miR-33-3p and 
miR-33-5p are evaluated in the MWCNT instilled mice (Figure 11).  The 
expression of miR-33-5p was increased 7.5 fold while miR-33-3p was not 
affected in C57Bl/6 mice instilled with MWCNT compared to those instilled with 
vehicle control.   
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Figure 10: Expression of ABCA1 and ABCG1 is dysregulated in C57Bl/6 mice instilled 
with MWCNT.  ABCA1 is decreased 40% in MWCNT instilled animals and ABCG1 
expression is decreased 30% in MWCNT instilled animals compared to vehicle controls. 
Graphs represent mean fold change compared to vehicle control. 
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4.5 In vivo rosiglitazone treatment increased miR-27b-3p in alveolar 
macrophages from C57Bl/6 mice instilled with MWCNT 
The inflammatory phenotype observed in the MWCNT model may be due 
to the deficiency of PPARγ expression.  The effect of rosiglitazone treatment on 
PPARγ and microRNA expression was evaluated in C57Bl/6 MWCNT instilled 
mice.  The expression of miR-27b-3p increased 1.5 fold in MWCNT mice treated 
with rosiglitazone compared to vehicle control animals. Evaluation of 
PPARγ mRNA and miR-27a-3p showed no difference between rosiglitazone 
injected mice and vehicle controls (Figure 12). 
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Figure 11: Expression of microRNA targeting ABC Transporters.  The expression 
of miR-33-5p was elevated in C57Bl/6 mice instilled with MWCNT compared to control 
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Figure 12: Expression of microRNA from C57Bl/6 mice with rosiglitazone treatment 
shows miR-27b-3p increased 1.5 fold after rosiglitazone treatment compared to animals 
receiving vehicle alone. Mean fold change is compared to vehicle control. 
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Figure 13:  Expression of inflammatory microRNA inC57Bl/6 mice increase in 
MWCNT instilled mice treated with rosiglitazone.  Graph represents mean fold change 
compared to vehicle control.   
 
 
 
 
 
 
4.6 In vivo rosiglitazone treatment increased miRNA associated with NF-κB 
regulation in MWCNT instilled C57Bl/6 mice 
 An inflammatory phenotype is observed in C57Bl/6 mice instilled with 
MWCNT [25]. The effect of PPARγ agonist rosiglitazone was evaluated on the 
expression of microRNA that may regulate NF-κB (Figure 13). Rosiglitazone 
injections increased the expression miR-146a-5p expression 1.6 fold in MWCNT 
instilled mice receiving rosiglitazone injections.  The expression of miR-23b-3p 
and miR-199a-3p was not altered in MWCNT instilled mice. 
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4.7 ABC Transporters are dysregulated in MWCNT instilled C57Bl/6 mice 
and can be affected with rosiglitazone treatment 
 The effects of rosiglitazone injections on ABC Transporter expression 
were evaluated in C57Bl/6 mice instilled with MWCNT.  The expression of 
ABCA1 expression was increased 1.5 fold in C57Bl/6 mice instilled with MWCNT 
then given rosiglitazone injections.  The expression of ABCG1 increased 1.4 fold 
in C57Bl/6 mice instilled with MWCNT given rosiglitazone injections. (Figure 14) 
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Figure 14: Rosiglitazone effects expression of ABC Transporters in MWCNT instilled 
mice.  ABCA1 and ABCG1 expression are increased in MWCNT instilled animals 
receiving rosiglitazone. Graphs represent mean fold change compared to vehicle controls.  
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Figure 15: Expression of mR-33-5p in MWCNT instilled mice increased with 
rosiglitazone treatment.  Graphs represent mean fold change compared to vehicle 
controls.  
4.8 Expression of microRNA targeting lipid transporters evaluated in 
MWCNT model 
The expression of the microRNA targeting the ABC Transporters is 
evaluated in MWCNT instilled C57Bl/6 mice treated with rosiglitazone (Figure 
15).  Rosiglitazone induced a 2.3 fold increase in miR-33-5p expression. The 
expression of miR-33-3p was not changed, however compared to animals 
receiving vehicle control. 
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 Table 2:  Summary of results presented in Chapter 4  
mRNA/microRNA C57Bl/6+MWCNT* C57Bl/6+MWCNT+Rosi** 
PPARγ mRNA Decreased Unchanged 
ABCA1 mRNA Decreased Increased 
ABCG1 mRNA Decreased Increased 
miR-27b Increased Increased 
miR-146a Increased Increased 
miR-23b Increased Unchanged 
miR-199a Unchanged Unchanged 
mIR-33-5p Increased Increased 
 
* Compared to PBS/Surfactant treated mice 
** Compared to vehicle control treated MWCNT 
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Summary/Discussion: 
Sarcoidosis is a chronic granulomatous disease which primarily affects the 
lung.  The etiology is unknown, but recent studies have suggested that 
environmental factors including carbon nanotubes may play a role in granuloma 
formation [44].  Previous animal models were limited because of the lack of 
chronicity.  Our laboratory has developed a model of chronic granulomas using 
MWCNT [25].  Studies showing that the deficiency of PPARγ in knock out mice 
affected microRNA expression (chapter 3) prompted our investigation of miRNAs 
in the MWCNT model of granulomatous lung disease.  Previous observations 
have shown deficient PPARγ in the alveolar macrophages of MWCNT instilled 
mice [31].  The expression of microRNA and their predicted targets were 
evaluated in MWCNT instilled mice.  We have found that miR-27b which has 
been shown in other systems to downregulate PPARγ is increased [45,46].  We 
also determined that PPARγ regulated genes ABCA1 and ABCG1 were 
downregulated.  Interestingly, both ABCA1 and ABCG1 are recognized as 
suppressors of proinflammatory cytokines in addition to their functions as 
facilitators of lipid metabolism [47,48].  We investigated miR-33 expression which 
was also elevated.  miR-33 has been shown to downregulate the expression of 
ABCA1 and ABCG1 in other systems [42,49].  NF-κB activation is an important 
driver of miR-33 expression [50].  Earlier studies demonstrated the up regulation 
of NF-κB in alveolar macrophages of patients with sarcoidosis [51].  Based on 
the involvement of NF-κB in granulomatous disease and the upregulation of miR-
23b, miR-146a and miR-199a in alveolar macrophages from PPARγ-KO mice, we 
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next investigated these miRNAs activated by NF-κB.  Both miR-23b and miR-
146a were upregulated, surprisingly miR-199a was not changed.  
In order to begin to understand the relationship between these identified 
genes and microRNAs, we decided to investigate the in vivo effects of a PPARγ 
agonist, rosiglitazone.  As a PPARγ ligand, rosiglitazone would not be expected 
to increase PPARγ expression but PPARγ activity should be enhanced.   As 
expected PPARγ gene expression was not altered with ligand, but increased 
activity was triggered. The PPARγ regulated genes, ABCA1 and ABCG1 mRNA 
expression were enhanced with rosiglitazone treatment.   
Surprisingly, miR-27b was also enhanced but miR-27b may be more 
involved in gene expression of PPARγ rather than activity.  We expected miR-33 
to be down regulated because of the enhanced expression of ABCA1 and 
ABCG1.  This increase of miR-33-5p and increase in mRNA of the ABC 
transporters would suggest that in this system, miR-33-5p is not efficient in 
regulating the transporters.  Whether increased PPARγ activity has an effect on 
miR-33 expression has not been previously reported.  In our in vivo system this 
upregulation of miR-33 could be an indirect effect.  The histopathology of 
rosiglitazone treated mice must be investigated before conclusions can be draw 
with regard to the efficacy of PPARγ ligand therapy.  It may also be necessary to 
extend the dosing schedule for rosiglitazone beyond 10 days in order for 
definitive changes to be seen in granuloma formation.   
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Further investigations are necessary to sort out the complex inter-
relationships between microRNA and altered gene expression in our MWCNT 
granulomatous disease model.   
(See Appendix C, Figures A-E)
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Appendix B: DCT VALUES USED FOR DATA 
Figure 2: Expression of microRNAs targeting PPARγ 
miR-27a-3p C57Bl/6 PPARγ-KO GM-CSF-KO 
C57 Control       
1478 0.12     
1479 0.14     
1480 0.78     
1481 0.16     
        
PPARγ-KO Control       
1501   -0.640   
1502   0.260   
1503   0.350   
1849   -0.100   
1850   -0.400   
1851   0.000   
1852   0.300   
        
GMKO Control       
1611     -0.24 
1613     0.06 
1683     -0.30 
1685     -0.40 
1687     -0.10 
1691     0.10 
    
miR-27b-3p C57Bl/6 PPARγ-KO GM-CSF-KO 
C57 Control       
1478 2.72     
1479 2.63     
1480 2.38     
1481 2.13     
        
PPARγ-KO Control       
1501   0.44   
1502   1.13   
1503   1.68   
1849   1.20   
1850   0.60   
1851   1.20   
1852   1.60   
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GMKO Control       
1611     0.13 
1613     0.01 
1683     0.33 
1685     0.51 
1687     1.14 
1691     0.56 
    
    
 
Figure 3: Expression of microRNA associated with NF-κB activity 
miR-23b-3p C57Bl/6 PPARγ-KO GM-CSF-KO 
C57 Control       
1478 2.57     
1479 2.55     
1480 2.83     
1481 2.30     
1482 2.95     
        
PPARγ-KO Control       
1500   -1.80   
1501   -1.74   
1502   -1.52   
1503   -1.18   
1849   1.40   
1850   0.60   
1851   1.10   
1852   1.60   
        
GMKO Control       
1611     -1.94 
1613     -2.58 
1683     0.01 
1685     0.14 
1687     0.77 
1691     -0.48 
 
miR-146a-5p C57Bl/6 PPARγ-KO GM-CSF-KO 
C57 Control       
1478 6.66     
1479 6.36     
1480 5.44     
48 
 
1481 5.95     
1482 5.67     
        
PPARγ-KO Control       
1500   2.46   
1501   2.16   
1502   3.10   
1503   3.03   
1849   2.90   
1850   3.40   
1851   4.20   
1852   4.10   
        
GMKO Control       
1611     -1.00 
1613     -1.20 
1683     0.80 
1685     1.20 
1687     1.30 
1691     1.60 
 
miR-199a-3p C57Bl/6 PPARγ-KO GM-CSF-KO 
C57 Control       
1478 11.55     
1479 11.27     
1480 12.11     
1481 10.75     
1482 11.88     
        
PPARγ-KO Control       
1500   9.32   
1501   8.69   
1502   9.05   
1503   8.15   
1849   10.90   
1850   9.30   
1851   10.10   
1852   11.00   
        
GMKO Control       
1611     5.20 
1613     5.20 
1683     7.90 
1685     7.96 
1687     8.63 
1691     7.03 
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Figure 4: miR-33-3p and miR-33-5p expression in GM-CSF-KO and PPARγ-KO 
miR-33-3p C57Bl/6 PPARγ-KO GM-CSF-KO 
C57 Control       
1478 11.61     
1479 11.50     
1480 12.28     
1481 12.29     
        
PPARγ-KO Control       
1501   10.21   
1502   11.30   
1503   11.14   
1849   4.20   
1850   3.60   
1851   4.60   
1852   5.60   
        
GMKO Control       
1683     10.47 
1685     10.23 
1687     10.43 
1691     11.12 
 
miR-33-5p C57Bl/6 PPARγ-KO GM-CSF-KO 
C57 Control       
1478 9.64     
1479 10.09     
1480 10.08     
1481 8.99     
1482 9.51     
        
PPARγ-KO Control       
1500   7.33   
1501   7.14   
1502   7.58   
1503   7.92   
1849   5.60   
1850   5.20   
1851   5.50   
1852   5.60   
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GMKO Control       
1611     8.77 
1613     7.87 
1612     8.01 
1620     10.07 
1683     9.57 
1685     10.51 
1687     8.16 
1691     12.64 
 
Figure 5: Expression of miR-27b-3p in rosiglitazone treated GM-CSF-KO 
miR-27b-3p GMCSF-KO+DMSO GMCSF-KO+Rosi 
GMKO+10d DMSO     
1925 0.95   
1926 0.98   
1927 0.78   
1946 1.60   
1947 0.90   
1948 1.20   
1949 2.30   
      
GMKO+10d Rosi     
1920   1.4 
1921   1.4 
1922   1.6 
1923   2.1 
1924   2.5 
1943   1.6 
1944   2.3 
 
 
 
 
Figure 6: PPARγ-KO mice treated with rosiglitazone 
miR-33-5p PPARγ-KO+DMSO PPARγ-KO+Rosi 
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PPARγ-KO+DMSO     
1966. 6.6   
1967 4.8   
1968 4.8   
1969 4.3   
1970 5.1   
      
PPARγ-KO+Rosi     
1971   9.5 
1972   10.1 
1973   8.5 
1974   10.4 
1975   9.9 
 
Figure 7: Expression of microRNA 146a-5p 
6 hour  US LPS Rosi GW Rosi+LPS GW+LPS 
1765 3.5000 3.00 4.10 4.00 3.10 3.00 
1774 3.9000 2.70 4.20 4.30 4.40 3.00 
1779 2.9000 2.50 4.30 3.80 2.70 2.70 
1838 2.7000 2.00 3.00 3.70 2.40 2.40 
       
24 Hour US LPS Rosi GW Rosi+LPS GW+LPS 
1748 3.0 1.0 3.8 3.5 1.7 3.3 
1756 3.4 .15 3.1 3.8 1.3 -.7 
1760 3.0 .5 3.2 2.8 1.5 .9 
 
Figure 8: Expression of microRNA in C57Bl/6 mice instilled with MWCNT 
PPARγ mRNA C57 60d PBS/Surf C57 60d MWCNT 
   
C57 60d PBS/Surfactant      
1703 1.7   
1704 2.1   
1889 2.4   
1890 2.1   
      
C57 60d MWCNT     
1713   2.6 
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1714   2.8 
1717   3.4 
1720   2.4 
1726   2.5 
 
miR-27b-3p C57 60d MWCNT C57 60d PBS/Surf 
   
C57+MW     
1573 0.75   
1574 0.85   
1575 0.89   
1495 1.02   
      
C57 60d PBS/Surf     
1703   1.6 
1704   1.5 
1705   1.5 
1889   0.9 
1890   2.2 
1892   2.6 
 
Figure 9: Expression of inflammatory microRNA in C57Bl/6 mice 
miR-23b-3p C57 60d MWCNT C57 60d PBS/Surf 
   
C57+MW     
1573 1.54   
1574 1.39   
1575 1.04   
1495 1.45   
1893 0.90   
1894 1.30   
1895 2.00   
      
C57 60d PBS/Surf     
1703   1.7 
1704   1.9 
1705   2.1 
1890   2.3 
1892   2.2 
miR-146a-5p C57 60d MWCNT C57 60d PBS/Surf 
   
C57+MW     
1573 4.41   
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1574 4.49   
1575 3.99   
1495 4.58   
      
C57 60d PBS/Surf     
1703   6.2 
1704   6.6 
1705   5.6 
1890   5.6 
1892   5.7 
 
Figure 10: Expression of ABCA1 and ABCG1 
ABCA1 mRNA C57 60d PBS/Surf C57 60d MWCNT 
C57 60d PBS/Surfactant      
1703 2.0   
1704 2.1   
1705 2.3   
1889 2.6   
1890 2.5   
      
C57 60d MWCNT     
1717   2.9 
1720   3.3 
1726   3.4 
1794   2.6 
1795   2.9 
1675   2.4 
 
ABCG1 mRNA C57 60d PBS/Surf C57 60d MWCNT 
C57 60d PBS/Surfactant      
1703 -1.0   
1704 -0.4   
1705 -0.7   
1889 -0.4   
1890 -0.4   
      
C57 60d MWCNT     
1717   0.60 
1720   0.20 
1726   0.70 
1794   -0.10 
1795   -0.04 
1675   -0.50 
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Figure 11: Expression of microRNA targeting ABC Transporters 
miR-33-5p C57 60d MWCNT C57 60d PBS/Surf  
C57 60d MWCNT     
1573 5.92   
1574 5.67   
1575 5.86   
1495 6.48   
      
C57 60d PBS/Surf     
1703   9.1 
1704   8.2 
1705   8.7 
1889   4.4 
1890   5.0 
1892   5.2 
 
Figure 12: Expression of microRNA from C57Bl/6 mice with rosiglitazone 
treatment 
 
miR-27b-3p C57 60d MWCNT C57 60d PBS/Surf  
   
C57 60d MWCNT     
1573 0.75   
1574 0.85   
1575 0.89   
1495 1.02   
      
C57 60d PBS/Surf     
1703   1.6 
1704   1.5 
1705   1.5 
1889   0.9 
1890   2.2 
1892   2.6 
 
Figure 13: Expression of inflammatory microRNA inC57Bl/6 mice 
 
miR-146a-5p C57 MW+ DMSO C57 MW+Rosi 
   
C57 MW+DMSO     
1928 5.10   
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1929 5.10   
1988 5.70   
1989 5.60   
1996 6.10   
1997 5.70   
      
C57 MW+Rosi     
1909   4.19 
1910   4.39 
1911   4.59 
1933   5.50 
1934   5.80 
1978   5.10 
1979   5.20 
1980   5.00 
1981   4.40 
 
 
Figure 14: Rosiglitazone effects expression of ABC Transporters in MWCNT 
 
ABCA1 C57 MW+ DMSO C57 MW+Rosi 
   
C57 MW+DMSO     
1988 2.9   
1989 3.3   
1996 3.4   
1997 2.6   
      
C57 MW+Rosi     
1908   2.3 
1909   2.8 
1910   3.1 
1978   2.3 
1979   2.6 
1980   2.5 
1981   2.4 
 
ABCG1 C57 MW+ DMSO C57 MW+Rosi 
   
C57 MW+DMSO     
1988 0.01   
1989 -0.40   
1996 -0.10   
1997 -0.10   
      
C57 MW+Rosi     
1908   -1.10 
1909   -0.60 
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1910   -0.40 
1978   -0.90 
1979   -0.70 
1980   -0.60 
1981   -0.60 
 
 
Figure 15: Expression of mR-33-5p in MWCNT instilled mice 
 
ABCG1 C57 MW+ DMSO C57 MW+Rosi 
   
C57 MW+DMSO     
1928 6.50   
1929 6.50   
1988 8.80   
1996 8.90   
1997 6.60   
      
C57 60d MW+10d Rosi Inj     
1909   6.71 
1910   6.56 
1911   6.93 
1933   6.20 
1934   6.50 
1978   5.90 
1979   5.90 
1980   6.40 
1981   5.50 
 
 
  
APPENDIX C: PROPOSED MECHANISIMS
 
  
Figure A: Proposed interaction of miR
and ABC Transporters.  miR
miR-33-3p and miR-33-5p targets that of ABCA1 and ABCG1.
 
 
Figure B: Regulation of NF
miR-146a expression. miR-146a targets upstream activators of NF
been shown to decrease NF-κ
 
 
 
 
-27b and miR-33-3p/5p with PPAR
-27b targets the messenger RNA of PPAR
 
 
-κB by miR-146a.  NF-κB acts as a promoter for 
-κB and has 
B activity [38]. 
 
 
γ 
γ while 
  
 
Figure C: Proposed effect of miR
and miR-199a have been reported to target the mRNA of IKK Kinase subunits 
[38,39].  Inhibition of IKK Kinase may decrease NF
 
 
 
 
 
 
Figure D: Effects of MWCNT exposure on gene and microRNA expression
alveolar macrophage.  
 
 
 
 
 
 
  
 
-23b and miR-199a on NF-κB activity.  miR
-κB activity. 
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 of the 
  
Figure E: Effect of rosiglitazone treatment on gene and microRNA expression in 
MWCNT instilled animals.  
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